spacer
home > ebr > summer 2002 > post-translational modifications of biopharmaceuticals - a challenge for analytical characterisation
PUBLICATIONS
European Biopharmaceutical Review

Post-Translational Modifications of Biopharmaceuticals - A Challenge for Analytical Characterisation

The list of biopharmaceuticals produced by recombinant DNA technology, transgenics and synthetic manufacture continues to grow to encompass therapeutic and diagnostic agents ranging from antibodies to vaccines. Regardless of the method of production, all these products present the biotechnology community with complex challenges in manufacture and, ultimately, analytical characterisation. Recognising the importance of this topic, a recent international conference was held on 'The Impact of Post-Translational and Chemical Modifications on Protein Therapeutics' (1). At this meeting of leading scientists from academia and industry, a keynote address was given by Dr Keith Weber, Deputy Director, Division of Monoclonal Antibodies, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research (CBER), FDA. Dr Weber presented the current CBER perspective on post-translational and chemical modifications, emphasising above all that CBER's primary concerns are "safety, purity, potency and strength of bioproducts".


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Fiona Greer and Dr Andrew Reason of M-Scan Ltd (UK) and Dr Mark Rogers of M-Scan Inc (US)
Dr Fiona Greer, Dr Andrew Reason and Dr Mark Rogers are principals of M-Scan (Mass Spectrometry Consultants and Analysts). Together, they have over 45 years' experience in the analysis of proteins and carbohydrates using mass spectrometry.
Following a PhD in Protein Biochemistry from Aberdeen University, Fiona joined M-Scan in 1984 to develop analytical services using the then new techniques of biopolymer mass spectrometry. She is Director of Biochemistry and VP of M-Scan Ltd, M-Scan SA and M-Scan Inc, and is also responsible for QA at all three laboratories.
Andrew received his PhD in Biochemistry from Imperial College, University of London in 1992 and joined M-Scan in 1994. He is Managing Director of M-Scan Ltd, Wokingham, UK.
Mark received his PhD in Biochemistry from the University of Westminster, London and has been with M-Scan for 13 years. He is currently Vice President of M-Scan Inc, Pennsylvania, US.

spacer
Dr Fiona Greer
spacer
spacer
spacer
Dr Andrew Reason
spacer
spacer
spacer
Dr Mark Rogers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisalas world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement